research 022 Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopeciaareata in pre-clinical models
The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris
Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
research Topical nitrogen mustard in the treatment of alopecia areata: a bilateral comparison study
Nitrogen mustard was not very effective for hair regrowth in alopecia areata and has potential skin cancer risk.
research Novel diagnostic tools and markers for inflammatory skin diseases
A new test using NOS2 and CCL27 genes can better diagnose and treat psoriasis and eczema.
research Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
research A Case Report of Cronkhite-Canada Syndrome Complicated by Membranous Nephropathy
Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.
research Alopecia areata: Time for position statement to include new systemic therapeutic advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo® hair growth factor formulation: A phase‐IV, open‐label, single‐arm multi‐ethnicity clinical trial
QR678 Neo® is a safe and effective treatment for hair loss in men and women.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research MitoQ enhances CYP19A1 expression to stimulate WNT/β-catenin signaling pathway for promoting hair growth in androgenetic alopecia
MitoQ may help treat hair loss by boosting hair growth pathways.
research 43225 Randomized study to assess the efficacy of a facial cosmetic product with nanoencapsulated cysteamine in women presenting melasma
The cosmetic product improved melasma and skin quality without causing irritation.
research Topical cetirizine for treating androgenetic alopecia: A systematic review
1% topical cetirizine may help treat hair loss but is less effective than minoxidil.
research Novel anti‐dandruff shampoo incorporated with ketoconazole‐coated zinc oxide nanoparticles using green tea extract
The new anti-dandruff shampoo with ketoconazole-coated zinc oxide nanoparticles is more effective against dandruff.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research 548 Deletion of Myelin Protein Zero-like 3 increases sebaceous gland size and sebocyte proliferation but reduces skin adipose depots: Can MPZL3 inhibition promote excessive loss of lipids via sebum hypersecretion?
Deleting MPZL3 increases skin oil production and reduces body fat.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research The investigation of selective sphingosine-1 phosphate receptor 1&4 modulator to treat alopecia areata mouse model
NXC736 significantly reduced hair loss in mice with alopecia areata.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research RASopathic alopecia: Hair changes associated with vemurafenib therapy
Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
research NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
research Nifedipine: a new treatment for perniosis
Nifedipine may help treat perniosis, improving symptoms and clearing lesions for some patients.
research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata
Ritlecitinib works well and is safe for treating alopecia areata.
research Granzyme B in Autoimmune Skin Disease
Granzyme B is important in autoimmune skin diseases and could be a new treatment target.